126385-78-2

Basic information

• Product Name: methyl (1r,4r)-4-benzamidocyclohexane-1-carboxylate
• Synonyms: methyl (1r,4r)-4-benzamidocyclohexane-1-carboxylate
• CAS NO: 126385-78-2
• Molecular Weight: 261.321
• Mol File: 126385-78-2.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: methyl (1r,4r)-4-benzamidocyclohexane-1-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl (1r,4r)-4-benzamidocyclohexane-1-carboxylate(126385-78-2)
• EPA Substance Registry System: methyl (1r,4r)-4-benzamidocyclohexane-1-carboxylate(126385-78-2)

Safety Data

• Hazardous Substances Data: 126385-78-2(Hazardous Substances Data)

Upstream product

• 61367-07-5 trans-4-aminocyclohexylcarboxylic acid methyl ester hydrochloride 
• 98-88-4 benzoyl chloride 
• 150-13-0 4-amino-benzoic acid 
• 175867-59-1 methyl 4-aminocyclohexane-1-carboxylate 
• 1776-53-0 4-aminocyclohexanecarboxylic acid 
• 126385-81-7 4-dibenzoylaminocyclohexanecarboxylate 

Downstream Products

• 126385-82-8 (D,L)-trans 4-aminocyclohexylglycine hydrochloride 
• 126385-80-6 trans 4-benzoylaminocyclohexanecarboxaldehyde 
• 126455-21-8 (D,L)-trans 4-guanidinocyclohexylglycine 
• 126455-18-3 (D,L)-trans 4-guanidinocyclohexylglycine methyl ester dihydrochloride 
• 60601-17-4 trans 4-benzoylaminocyclohexanemethanol 

Relevant articles and documents

Discovery of clinical candidate (1 R,4 r)-4-((R)-2-((S)-6-Fluoro-5 H-imidazo[5,1-A[isoindol-5-yl)-1-hydroxyethyl)cyclohexan-1-ol (Navoximod), a potent and selective inhibitor of indoleamine 2,3-dioxygenase 1

A novel class of 5-substituted 5H-imidazo[5,1-a]isoindoles are described as potent inhibitors of indoleamine 2,3-dioxygenase 1 (IDO1). A structure-based drug design approach was used to elaborate the 5H-imidazo[5,1-a]isoindole core and to improve potency and pharmacological properties. Suitably placed hydrophobic and polar functional groups in the lead molecule allowed improvement of IDO1 inhibitory activity while minimizing off-target liabilities. Structure-activity relationship studies focused on optimizing IDO1 inhibition potency and a pharmacokinetic profile amenable to oral dosing while controlling CYP450 and hERG inhibitory properties.